We demonstrated that the tumor suppressor MDHDH might act as a clinical biomarker and that the overexpression of MDHDH might be a novel synergistic strategy for enhancing metabolism-based, epigenetic-based, and autophagy regulation-based therapies, thereby fulfilling clinical benefits for glioblastoma multiforme patients. Here, LINC00632 is linked to glioblastoma.